Peptide therapy on TikTok: separating gym hype from actual data

What did @braeden_turay5 actually say?

The creator is advising on when to inject GHRP-2 (which they call "GHRB2" and "GHRP to win" throughout), specifically to maximize both growth hormone release and appetite stimulation. Their core recommendation: pin on a relatively empty stomach, ideally before a meal you're struggling to eat. They also recommend pairing GHRP-2 with a glucose disposal agent (GDA), specifically naming a product called "SLIN." They describe vivid personal hunger effects, including compulsive eating and what sounds like a binge-eating episode, framing it as something to manage rather than a red flag. They close with a brief note that the GH effect "is not going to be super physiological" but may help maintain or boost low levels.

Worth noting: the transcript is messy and informal, and several statements are incomplete or ambiguous. That matters when someone is taking dosing advice from a short TikTok video.

Does the science back this up?

On the timing question, they're largely correct, though not for the reasons they imply. The literature does support fasted or low-glucose states for GHRP-2 administration, but the GDA recommendation is less evidence-based than they make it sound.

GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHSR-1a). Studies confirm that elevated blood glucose and elevated free fatty acids both blunt the GH pulse triggered by GHRP-2. Broglio et al. (2001, Journal of Clinical Endocrinology and Metabolism) demonstrated that oral glucose administration significantly attenuated GH release following ghrelin analog administration. This is the pharmacological basis for the "empty stomach" advice, and it's sound.

The GDA recommendation is trickier. There's no peer-reviewed evidence that a commercial GDA product specifically improves GHRP-2 efficacy. What the creator may be gesturing at is simply managing postprandial glucose spikes when you do eat after pinning, to preserve the GH window. That's a reasonable practical concern, but calling it evidence-based would be a stretch.

What did they get wrong (or right)?

They got the fasted-state timing right. That part is grounded in real pharmacology.

What they got wrong, or at least dangerously underplayed: the hunger and compulsive eating effects they describe are not a fun quirk to "be careful" about. GHRP-2 substantially elevates ghrelin, a peptide with well-documented roles in reward-driven eating behavior. Naleid et al. (2005, Peptides) showed ghrelin administration in rodents increased motivation for highly palatable food independent of caloric need. The creator describes eating "until you're sick and then you keep eating" as a personal anecdote and moves on. That's a description of loss-of-control eating, which in a population already prone to disordered eating around food and body image, is not something to gloss over.

The claim that the GH effect "will help maintain levels or boost if you're low" is vague to the point of being misleading. GHRP-2 stimulates endogenous GH secretion; it does not replace or directly supplement GH levels. The magnitude of response varies considerably based on age, body composition, somatostatin tone, and baseline GH status. Presenting it as a reliable level-booster without that context oversimplifies the pharmacology.

What should you actually know?

GHRP-2 is a research peptide. It is not FDA-approved for any human indication, and its compounded forms vary in purity and concentration. If you are considering any peptide protocol, you need a prescribing clinician who can assess your baseline IGF-1, GH axis function, and metabolic markers, not a TikTok timing guide.

The timing advice (fasted state, avoid high glucose around administration) is pharmacologically reasonable and consistent with how GHRP-2 studies have been designed. The GDA recommendation is speculative and not directly supported by clinical literature on GHRP-2. The hunger side effects described are a real and documented consequence of ghrelin receptor activation, not a harmless quirk. Anyone with a personal or family history of disordered eating should treat ghrelin-pathway peptides with significant caution.

The creator also never mentions that "too much" GHRP-2 can elevate cortisol and prolactin, which have their own downstream effects. That omission matters. Raun et al. (1998, European Journal of Endocrinology) documented dose-dependent prolactin and cortisol responses to GHRP-2 in human subjects.